

AMC LAPIS GLOB TOP 25 GEN REVOL



PRODUCT STRATEGY

The AMC on "LAPIS GLOBAL TOP 20 GENOMIC REVOLUTION" is an actively managed portfolio of equities, which is based on investment advice and recommendation by Lapis Asset Management AG. The Lapis Global Top 25 Genomic Revolution is composed of the worldwide best-known and leading top 20 companies (gene therapy, bioinformatics, bio-inspired computing, molecular medicine, pharmaceutical innovation) based on the research approach of an internationally recognized company. All stocks are equally weighted and the certificate is rebalanced on a quarterly basis (end of January, April, July and October).

FACTS AND FIGURES

ISIN	CH1103333931
Currency	USD
Maturity Date	Open End
NAV Date	10.01.2024
Valor	110333393
Dividend	Reinvested
FX Overlay	Disabled
Issue Date	19.05.2021
NAV	53.60
Mgmt Fee (total, p.a.)	1.35%
Rebalancing	Quarterly
AuM	USD 412'569
Components	26
Certificates	7'690
Issuer	Bank Julius Baer
Last Rebalancing	02.11.2023


PERFORMANCE

1 month	9.05%	52 week high	66.00
3 months	4.18%	52 week low	45.95
1 year	-14.85%	All-time high	123.40
Since inception	-46.4%	All-time low	43.45
YTD	0.09%	Max draw down	-64.79%

PRICE CHART




PERFORMANCE HEAT MAP




UNDERWATER CURVE




PERFORMANCE ANNUAL



PRODUCT COMPOSITION BY COUNTRY




PRODUCT COMPOSITION BY CURRENCY



COUNTRY EXPOSURE MAP

USA	73.14%
Switzerland	7.8%
Netherlands	4.17%
China	4.06%
Germany	3.81%
Ireland	3.67%
N/A	3.35%



COMPOSITION

CASH

Short name	Name	ISIN	Currency	Units / AMC	Total units	Percentage
USD	USD	-	USD	1.8449099	14'187.3571745	3.35%

STOCKS

Short name	Name	ISIN	Currency	Units / AMC	Total units	Percentage
MRNA US	MODERNA INC	US60770K1079	USD	0.02564625	197.2196406	5.1%
RGEN US	REPLIGEN CORP	US7599161095	USD	0.01539555	118.3917415	4.98%
RVTY US	REVVITY INC	US7140461093	USD	0.02216474	170.4468175	4.5%
TECH US	BIO-TECHNE CORP	US09073M1045	USD	0.032684	251.33996	4.35%
ILMN US	ILLUMINA INC	US4523271090	USD	0.01686727	129.7093426	4.31%
A US	AGILENT TECHNOLOGIES INC	US00846U1016	USD	0.018088	139.09672	4.31%
ALNY US	ALNYLAM PHARMACEUTICALS INC	US02043Q1076	USD	0.01200415	92.31188568	4.29%
CTLT US	CATALENT INC	US1488061029	USD	0.04604747	354.1050138	4.21%
QGEN US	QIAGEN N.V.	NL0012169213	USD	0.05110054	392.9631422	4.17%
TMO US	THERMO FISHER SCIENTIFIC INC	US8835561023	USD	0.004209	32.36721	4.16%
ABT US	ABBOTT LABORATORIES	US0028241000	USD	0.019739	151.79291	4.1%

LONN SW	LONZA GROUP AG-REG	CH0013841017	CHF	0.00525596	40.41833368	4.07%
IQV US	IQVIA HOLDINGS INC	US4626601053	USD	0.01031227	79.30137333	4.07%
VRTX US	VERTEX PHARMACEUTICALS INC	US92532F1003	USD	0.00519345	39.93760103	4%
BNTX US	BIONTECH SE-ADR	US09075V1026	USD	0.01977032	152.0337375	3.81%
ROG SW	ROCHE HOLDING AG-GENUSSCHEIN	CH0012032048	CHF	0.00688964	52.98131358	3.72%
ICLR US	ICON PLC	IE0005711209	USD	0.00778986	59.90399068	3.67%
HOLX US	HOLOGIC INC	US4364401012	USD	0.02799665	215.2942768	3.65%
DGX US	QUEST DIAGNOSTICS INC	US74834L1008	USD	0.01428708	109.8676395	3.56%
GILD US	GILEAD SCIENCES INC	US3755581036	USD	0.023055	177.29295	3.54%
SRPT US	SAREPTA THERAPEUTICS INC	US8036071004	USD	0.01611448	123.9203771	3.49%
BMJ US	BRISTOL-MYERS SQUIBB CO	US1101221083	USD	0.036003	276.86307	3.31%
BGNE US	BEIGENE LTD-ADR	US07725L1026	USD	0.01003465	77.16643833	3.19%
2359 HK	WUXI APPTec CO LTD-H	CNE100003F19	HKD	0.13084588	1'006.20485 11	2.25%
2269 HK	WUXI BIOLOGICS CAYMAN INC	KYG970081173	HKD	0.27724622	2'132.02344 92	1.8%

IMPORTANT LEGAL NOTICE

GENERAL This statement shall be deemed correct and approved unless Bank Julius Baer & Co. Ltd. receives written notification of disagreement within four weeks from the date of dispatch. The information and opinions expressed in this document were produced by Bank Julius Baer & Co. Ltd., Zurich, which is supervised by the Swiss Financial Market Supervisory Authority FINMA, as of the date of writing and are subject to change without notice. This document is intended for information purposes only and does not constitute an advice, offer or an invitation by, or on behalf of, Julius Baer to buy or sell any securities, securities based derivatives or other products or to participate in any particular trading strategy in any jurisdictions. Opinions and comments of the authors reflect their current views, but not necessarily of other Julius Baer entities or any other third party. Other Julius Baer entities may have issued, and may in the future issue, other documents that are inconsistent with, and reach different conclusions from, the information presented in this document. Julius Baer assumes no obligation to ensure that such other documents are brought to the attention of any recipient of this document. Entities within the Julius Baer Group, except Julius Baer Wealth Advisors (India), provide advice which is not considered «independent» in the sense given to that term by the EU Directive 2014/65/EU on markets in financial instruments (known as MiFID II). Prospectus, the key information documentation and other relevant documents are available free of charge from Bank Julius Baer & Co. Ltd., Bahnhofstrasse 36, 8001 Zurich. In addition, the key information document can be found at www.juliusbaer.com/product-information.

SUITABILITY Investments in the asset classes mentioned in this document may not be suitable for all recipients and may not be available in all countries. Clients of Julius Baer are kindly requested to get in touch with the local Julius Baer entity in order to be informed about the services and/or products available in their country. This document has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider the suitability of the transaction to individual circumstances and objectives. Any investment or trading or other decision should only be made by the client after a thorough reading of the relevant product term sheet, subscription agreement, information memorandum, prospectus or other offering document relating to the issue of the securities or other financial instruments. Nothing in this document constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to individual circumstances, or otherwise constitutes a personal recommendation to any specific investor. Julius Baer recommends that investors independently assess, with a professional advisor, the specific financial risks as well as legal, regulatory, credit, tax and accounting consequences.

INFORMATION / FORECASTS REFERRED TO Although the information and data herein are obtained from sources believed to be reliable, no representation is made that the information is accurate or complete. In particular, the information provided in this document may not cover all material information on the financial instruments or issuers of such instruments. Bank Julius Baer & Co. Ltd., Zurich, its subsidiaries and affiliated companies do not accept liability for any loss arising from the use of this document. Important sources for the production of this document are e.g. national and international media, information services (e.g. Reuters, Bloomberg Finance L.P.), publicly available databases, economic journals and newspapers (e.g. Financial Times, Wall Street Journal), publicly available company information, documents of rating agencies. Ratings and appraisals contained in this document are clearly marked as such. All information and data used for this document relate to past or present circumstances and may change at any time without prior notice. Statements contained in this document regarding financial instruments or issuers of financial instruments relate to the time of the production of this document. Such statements are based on a multitude of factors which are subject to continuous change. A statement contained in this document may, thus, become inaccurate without this being published. Potential risk regarding statements and expectations expressed in this document may result from issuer specific and general (e.g. political, economic, market, etc.) developments.

RISKS The price and value of, and income from investments in, any asset class mentioned in this document may fall as well as rise and investors may not get back the amount invested. Risks involved in any asset class mentioned in this document may include, but are not necessarily limited to, market risks, credit risks, political risks and economic risks. The investor may be exposed to currency risk when the product or underlyings of the product are denominated in currencies other than that of the country in which the investor is resident. The investment as well as its performance would therefore be exposed to currency fluctuations and may increase or decrease in value. Particular risks in connection with specific investments featured in this document are disclosed in the relevant product term sheet, subscription agreement, information memorandum, prospectus or other offering document relating to the issue of the securities or other financial instruments. These documents can be obtained free of charge upon request. Investments in emerging markets are speculative and may be considerably more volatile than investments in established markets. Clients should not be investing in the product unless they fully understand the feature and risks associated with it. This document may include figures relating to simulated past performance. This document may include figures relating to simulated past performance. Past performance, simulations and performance forecasts are not reliable indicators of future results. Shares, bank debt securities (e.g. interest bearing bank bonds and certificates) as well as other claims against financial institutions are subject to special regulations such as the “Bank Recovery and Resolution Directive” and the “Single Resolution Mechanism Regulation”. These regulations can have a negative effect for the investor / contractual partner of the financial institution in case of a default and the necessity of a resolution of the financial institution. For further details, please refer to: www.juliusbaer.com/legal-information-en.

Actively Managed Certificates (AMCs) are complex financial products which involve a high degree of risk. They are intended exclusively for investors who have the knowledge and experience necessary to understand all risks and merits involved. AMCs are not comparable with conventional debts or equity securities and will not be covered by any financial compensation or insurance scheme. In particular, the AMC does not constitute a participation in a collective investment scheme. It constitutes a direct, unconditional, unsecured and unsubordinated obligation of the issuer. The product's value is not only dependent on the development of the underlying(s), but also on the credit-worthiness of the issuer. As AMCs may be denominated in another currency than the one of the investor's home member state, fluctuations in exchange rates may adversely affect the market value of the product. AMCs were not registered with the local regulator and are not publicly distributable outside of Switzerland. Not all the risks and merits associated with an AMC can be disclosed in this publication. Therefore, potential investors should consult the entire product documentation related to the specific issuance before making any investment decision. The documentation can be obtained free of charge from your relationship manager or be requested at derivatives@juliusbaer.com. Bank Julius Baer & Co. Ltd. makes no representation as to the suitability or appropriateness of the product for any particular investor.

CONFLICTS OF INTEREST Julius Baer is required to disclose important information about its interests and potential conflicts.

In order to prevent conflicts of interest from adversely affecting the interests of its clients, Julius Baer has established a policy and procedures designed to identify and manage such conflicts. These include organisational and administrative arrangements to safeguard the interests of clients, adequate remuneration policies (for persons involved in the production of this document) based largely on qualitative criteria (e.g. overall quality and accuracy of research) and only remotely on quantitative elements (e.g. overall performance of Julius Baer). A Julius Baer entity may, to the extent permitted by law, participate or invest in other financing transactions with the issuer of the securities referred to herein, perform services or solicit business from such issuers, have a position or effect transactions in the securities or options thereof, have any other significant financial interest regarding the issuers of the securities referred to herein and/or may have done so in the past. For further information about our interest in the investments featured in this document, see the company-specific disclosures above.

IMPORTANT DISTRIBUTION INFORMATION This document and any market data contained therein shall only be for the personal use of the intended recipient and shall not be redistributed to any third party, unless Julius Baer or the source of the relevant market data gives their approval. This document is not directed to any person in any jurisdiction where (on the ground of that person's nationality, residence or otherwise) such documents are prohibited.

External Asset Managers (EAM)/External Financial Advisors (EFA): In case this document is provided to EAM/EFA, Julius Baer expressly prohibits its redistribution or any other way of making it available to clients and/or third parties. The document is of a purely abstract and general nature and is not intended for, nor directed at, client portfolios in general or clients domiciled in the European Economic Area in particular. By receiving any document, the EAM/EFA confirms that they will make their own independent analysis and investment decisions, where applicable.

Switzerland: This document is distributed by Bank Julius Baer & Co. Ltd., Zurich, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). Some of the investment funds mentioned in this document may not be authorised for distribution in Switzerland and may therefore only be distributed to qualified investors as defined in the Swiss Collective Investment Schemes Act and the Swiss Collective Investment Schemes Ordinance. Structured products do not constitute a participation in a collective investment scheme. Therefore, they are not supervised by the Swiss Financial Market Supervisory Authority FINMA and the investor does not benefit from the specific investor protection provided under the Swiss Federal Act on Collective Investment Schemes.

UNITED STATES: NEITHER THIS DOCUMENT NOR ANY COPY THEREOF MAY BE SENT, TAKEN INTO OR DISTRIBUTED IN THE UNITED STATES OR TO ANY US PERSON.

This document may contain information obtained from third parties, including ratings from rating agencies such as Standard & Poor's, Moody's, Fitch and other similar rating agencies, and research from research providers such as MSCI ESG Research LLC or its affiliates. Issuers mentioned or included in any MSCI ESG Research LLC materials may be a client of, or affiliated with, a client of MSCI Inc. (MSCI) or another MSCI subsidiary. Reproduction and distribution of third-party content in any form is prohibited except with the prior written permission of the related third party. Third-party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings or research, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third-party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third-party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings or research. Credit and/or research ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the market value of securities or the suitability of securities for investment purposes and should not be relied on as investment advice.

© Julius Baer Group, 2022